155 related articles for article (PubMed ID: 8120869)
1. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
Ducharme Y; Brideau C; Dubé D; Chan CC; Falgueyret JP; Gillard JW; Guay J; Hutchinson JH; McFarlane CS; Riendeau D
J Med Chem; 1994 Feb; 37(4):512-8. PubMed ID: 8120869
[TBL] [Abstract][Full Text] [Related]
2. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
[TBL] [Abstract][Full Text] [Related]
3. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Delorme D; Denis D; Falgueyret JP; Fortin R; Guay J; Hamel P
J Med Chem; 1993 Sep; 36(19):2771-87. PubMed ID: 8410991
[TBL] [Abstract][Full Text] [Related]
4. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM
J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908
[TBL] [Abstract][Full Text] [Related]
5. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
Hamel P; Riendeau D; Brideau C; Chan CC; Desmarais S; Delorme D; Dubé D; Ducharme Y; Ethier D; Grimm E; Falgueyret JP; Guay J; Jones TR; Kwong E; McAuliffe M; McFarlane CS; Piechuta H; Roumi M; Tagari P; Young RN; Girard Y
J Med Chem; 1997 Aug; 40(18):2866-75. PubMed ID: 9288168
[TBL] [Abstract][Full Text] [Related]
6. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Falgueyret JP; Guay J; Jones TR; Lépine C; Macdonald D; McFarlane CS
J Med Chem; 1994 Apr; 37(8):1153-64. PubMed ID: 8164257
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis of 5-lipoxygenase inhibitors: role of the substituents in chiral recognition and on the active conformations of the (methoxyalkyl)thiazole and methoxytetrahydropyran series.
Lambert-van der Brempt C; Bruneau P; Lamorlette MA; Foster SJ
J Med Chem; 1994 Jan; 37(1):113-24. PubMed ID: 8289184
[TBL] [Abstract][Full Text] [Related]
8. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
[TBL] [Abstract][Full Text] [Related]
9. (Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
Bird ; Bruneau P; Crawley GC; Edwards MP; Foster SJ; Girodeau JM; Kingston JF; McMillan RM
J Med Chem; 1991 Jul; 34(7):2176-86. PubMed ID: 1648621
[TBL] [Abstract][Full Text] [Related]
10. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase.
Crawley GC; Bird TG; Bruneau P; Dowell RI; Edwards PN; Foster SJ; Girodeau JM; McMillan RM; Walker ER; Waterson D
J Lipid Mediat; 1993; 6(1-3):249-57. PubMed ID: 8395247
[TBL] [Abstract][Full Text] [Related]
11. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
Lau CK; Bélanger PC; Dufresne C; Scheigetz J; Therien M; Fitzsimmons B; Young RN; Ford-Hutchinson AW; Riendeau D; Denis D
J Med Chem; 1992 Apr; 35(7):1299-318. PubMed ID: 1313879
[TBL] [Abstract][Full Text] [Related]
12. Methoxyalkyl thiazoles: a novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase.
McMillan RM; Bird TG; Crawley GC; Edwards MP; Girodeau JM; Kingston JF; Foster SJ
Agents Actions; 1991 Sep; 34(1-2):110-2. PubMed ID: 1793013
[TBL] [Abstract][Full Text] [Related]
13. Studies on 5-lipoxygenase inhibitors. I. Synthesis and 5-lipoxygenase-inhibitory activity of novel hydroxamic acid derivatives.
Yatabe T; Kawai Y; Oku T; Tanaka H
Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):966-72. PubMed ID: 9658575
[TBL] [Abstract][Full Text] [Related]
14. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
16. L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
Belanger P; Maycock A; Guindon Y; Bach T; Dollob AL; Dufresne C; Ford-Hutchinson AW; Gale PH; Hopple S; Lau CK
Can J Physiol Pharmacol; 1987 Dec; 65(12):2441-8. PubMed ID: 2835137
[TBL] [Abstract][Full Text] [Related]
17. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
Gillard J; Ford-Hutchinson AW; Chan C; Charleson S; Denis D; Foster A; Fortin R; Leger S; McFarlane CS; Morton H
Can J Physiol Pharmacol; 1989 May; 67(5):456-64. PubMed ID: 2548691
[TBL] [Abstract][Full Text] [Related]
18. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors.
Fischer L; Szellas D; Rådmark O; Steinhilber D; Werz O
FASEB J; 2003 May; 17(8):949-51. PubMed ID: 12670876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
